In vitro aging model having multilayer structure and manufacturing method therefor

The multilayer in vitro aging model with a glycated extracellular matrix structure addresses the limitations of two-dimensional models by accurately mimicking three-dimensional skin tissue, enhancing skin aging research and substance screening for anti-aging applications.

WO2024248588A1PCT designated stage expired Publication Date: 2024-12-05KOREA ADVANCED INST OF SCI & TECH
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/095850
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-30
Filing Date
2024-05-30
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current in vitro models, particularly for skin aging research, fail to accurately mimic the three-dimensional structure of tissues, leading to inadequate representation of complex intercellular interactions essential for understanding and addressing skin aging processes.

Method used

A multilayer in vitro aging model is developed, featuring a multilayer extracellular matrix structure that mimics the three-dimensional skin tissue by using a hydrophobic substrate coated with cell adhesion molecules, culturing cells, removing non-ECM components, and glycating the matrix to create a robust ECM structure.

Benefits of technology

This model effectively mimics the three-dimensional skin tissue structure, enabling more accurate research on skin aging and providing a tool for screening substances that inhibit or promote tissue aging, thereby aiding in the development of anti-aging pharmaceutical and cosmetic compositions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024095850_05122024_PF_FP_ABST
    Figure KR2024095850_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to an in vitro aging model having a multilayer structure and. more specifically, to an in vitro aging model for use in tissue aging research, including an extracellular matrix with a multilayer structure and to a manufacturing method thereof. The majority of the cellular structures of the individual are organized in three dimensions, which results in complex intercellular interactions that cannot be mimicked in two-dimensional monolayer cell cultures. Therefore, in order to develop highly bio-responsive technology in various fields such as research on diseases, customized medicine, and new drug development, there is an increasing need for an in vitro model that similarly mimics the shape of a three-dimensional cell structure. Since the in vitro aging model of the present invention implements the multi-layer ECM structure as it is, the in vitro aging model can mimic the three-dimensional structure of various tissues according to the type of cells to be applied. In particular, since being similar to the ECM structure of skin tissues, the in vitro aging model is expected to be largely used in skin aging research.
Need to check novelty before this filing date? Find Prior Art

Description

In vitro aging model with multilayer structure and method for manufacturing the same

[0001] The present invention relates to an in vitro aging model having a multilayer structure, specifically, to an in vitro aging model used in tissue aging research, characterized in that it includes an extracellular matrix having a multilayer structure, and a method for producing the same.

[0002] Most cellular structures in animals and plants, including humans, are organized three-dimensionally, resulting in complex cell-to-cell interactions that cannot be replicated in two-dimensional monolayer cell cultures. Therefore, the need for in vitro models that closely mimic the morphology of three-dimensional cell structures is increasing for the development of highly biocompatible technologies in diverse fields, including disease research, personalized medicine, and new drug development.

[0003] The skin, in particular, is an organ where maintaining and restoring its three-dimensional structure is crucial. In modern times, with the development of industrial society and increased social activity, self-awareness and the desire to actively express oneself have increased, leading to a growing interest in beauty and the prevention of skin aging. Furthermore, since the breakdown of the three-dimensional structure of skin tissue leads to wrinkles, loss of elasticity, and dryness, it is no exaggeration to say that the core of skin aging is the extracellular matrix (ECM), the connective tissue within the dermis.

[0004] Accordingly, the present invention has been conceived to address the above-mentioned problems, and relates to an in vitro aging model comprising a multilayered extracellular matrix, and a method for producing the same. The in vitro aging model of the present invention embodies the multilayered ECM structure, thereby enabling it to mimic the three-dimensional structure of various tissues depending on the type of cell applied. In particular, since it is similar to the ECM structure of skin tissue, it is expected to be of great use in skin aging research.

[0005] One object of the present invention is to provide a multilayered extracellular matrix structure, i.e., an in vitro aging model having a multilayered structure.

[0006] Another object of the present invention is to provide a method for manufacturing an in vitro aging model having the above multilayer structure.

[0007] Another object of the present invention is to provide a method for screening candidate substances for inhibiting tissue aging using the in vitro aging model having the above multilayer structure.

[0008] Another object of the present invention is to provide a method for evaluating the effect of a substance for inhibiting tissue aging using the in vitro aging model having the above multilayer structure.

[0009] Another object of the present invention is to provide a method for studying tissue aging using the in vitro aging model of the multilayer structure.

[0010] The above tissue may preferably be skin tissue, but is not limited thereto.

[0011] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by those skilled in the art from the description below.

[0012] Hereinafter, various embodiments described herein will be described with reference to the drawings. In the following description, various specific details, such as specific configurations, compositions, and processes, are set forth to provide a thorough understanding of the present invention. However, certain embodiments may be practiced without one or more of these specific details, or in conjunction with other known methods and configurations. In other instances, well-known processes and manufacturing techniques have not been described in specific detail so as not to unnecessarily obscure the present invention. Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, configuration, composition, or characteristic described in connection with the embodiment is included in one or more embodiments of the present invention. Thus, the appearances of "in one embodiment" or "an embodiment" in various places throughout this specification do not necessarily refer to the same embodiment of the present invention. Additionally, the particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments.

[0013] Unless otherwise specifically defined in the specification, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present invention belongs.

[0014] Throughout the specification, whenever a part is said to "include" a component, this does not mean that it excludes other components, but rather that it may include other components, unless otherwise stated.

[0015] Histologically, the skin is largely composed of three layers: the epidermis, an epithelial tissue; the dermis, a connective tissue located beneath it; and subcutaneous fat. The dermis, in particular, accounts for the majority of skin tissue and plays a crucial role in maintaining its structure and function. As we age, the cells and various components that make up the dermis undergo quantitative and qualitative changes, resulting in aging. When the dermis ages, visible changes occur, such as decreased skin elasticity, the formation of deep wrinkles, and skin that becomes drier than before. Therefore, it is no exaggeration to say that the core of skin aging is the extracellular matrix (ECM), the connective tissue within the dermis. The ECM, which makes up the majority of the dermis, is a complex meshwork that fills the gaps between cells. As a non-cellular part of the tissue, it creates an external environment for cells to survive healthily. The components of the dermal ECM are synthesized intracellularly by fibroblasts and secreted exocytotically. Representative examples include fibrous proteins such as collagen and elastin, amorphous matrix proteins such as proteoglycan complexes, and glycoproteins that connect cells and the matrix, such as fibronectin and laminin. The specific composition and characteristics of the ECM are summarized below.

[0016] [1] Amorphous substrate

[0017] ① Glycosaminoglycan (GAG)

[0018] - There are a total of 6 types: hyaluronic acid (HA), chondroitin sulfate (CS), dermatan sulfate (DS), heparin sulfate (HS), heparin (HP), and keratin sulfate (KS).

[0019] - It has a negative charge with carboxyl and sulfate groups and easily combines with water molecules to perform moisture retention function.

[0020] - GAGs usually do not exist alone and exist bound to another protein.

[0021] ② Proteoglycan (PG)

[0022] - It is a gel-type complex in which GAG and a specific protein (core protein) are combined.

[0023] - It acts as a cushion to fill the empty space between fibrous proteins.

[0024] - Helps retain moisture and allow various nutrients to move freely.

[0025] - It is involved in signal transmission between cells or various fibers.

[0026] [2] Fibrous structural protein

[0027] ① Collagen

[0028] - It is a triple helix structure in which various amino acids are connected in a true form.

[0029] - It makes up most of the dermis, and type I collagen and type III collagen are representative.

[0030] - Provides tension to support the skin's firm structure.

[0031] ② Elastin (elastic fiber)

[0032] - It acts like a spring and provides the elasticity and flexibility needed for the skin to return to its original shape.

[0033] [3] Fibrous adhesive protein

[0034] · Fibronectin

[0035] - It is a glycoprotein that connects cells and substrates to each other.

[0036] - It directly binds to integrin receptors located on the cell membrane surface and induces activity.

[0037] [4] Other

[0038] · Growth factors (EGF, FGF, VEGF, etc.), integrin receptors, matrix metalloproteinases (MMPs), etc.

[0039] In summary, the ECM in the dermis acts as a physical support structure that fills the space between cells, is involved in the supply of nutrients and moisture and the regeneration of damaged tissues, and performs the function of controlling interaction and communication with cells, so the breakdown of the ECM structure is directly related to skin aging.

[0040] Therefore, it is expected that the in vitro aging model including the extracellular matrix with a multilayer structure provided by the present invention can be usefully utilized for skin aging research.

[0041] In one aspect of the present invention, a method for producing a multilayer extracellular matrix structure is provided, comprising: (a) coating a hydrophobic substrate with cell adhesion molecules; (b) culturing cells on (a); (c) removing components other than the extracellular matrix from (b); and (d) glycating (c).

[0042] The above multilayered extracellular matrix structure is understood to have the same meaning as the multilayered in vitro aging model in the present invention.

[0043] The hydrophobic substrate is preferably made of glass, but is not limited thereto. The hydrophobic substrate may be used by converting its surface to hydrophilic through oxygen plasma treatment. In this case, the oxygen plasma treatment may be performed at an intensity of 30 W for 1 minute, but is not limited thereto. If a substrate with a hydrophilic surface is used, the oxygen plasma treatment step may be omitted.

[0044] The method for manufacturing a multilayered extracellular matrix structure of the present invention may further include, before coating cell adhesion molecules on a hydrophobic substrate, a step of treating the substrate with oxygen plasma and coating the substrate with an acrylate-based polymer resin. In this case, the acrylate-based polymer resin was selected because it satisfies the effect of firmly fixing the lowermost layer of extracellular matrix to a glass substrate (Adhesion strength), the effect of not interfering with cell survival due to excellent biocompatibility (Biocompatibility), and the effect of appropriately balancing flexibility and rigidity to support a multilayered extracellular matrix structure (Mechanical properties). The above acrylate polymer resin is methyl acrylate, ethyl acrylate, butyl acrylate, 2-carboxyethyl acrylate, methyl methacrylate, ethyl methacrylate, butyl methacrylate, hydroxyalkyl acrylate, hydroxyethyl methacrylate, hydroxyalkyl methacrylate, acrylamide, aminoalkyl acrylate, aminoalkyl methacrylate, tetra(ethylene glycol)dimethacrylate, hydroxypropyl methacrylate,It may be at least one selected from the group consisting of 2-hydroxyethyl acrylate, polyurethane acrylate, poly(methyl methacrylate), poly(glycidyl methacrylate), 1-vinyl-2-pyrrolidone, di(ethylene glycol)ethyl ether methacrylate, ethylene glycol methyl ether methacrylate, 3-sulfopropyldimethyl-3-methacrylamidopropyl-ammonium, acrylic acid, and methacrylic acid, but is not limited thereto.

[0045] The above cell adhesion molecule may be at least one selected from the group consisting of collagen, fibronectin, laminin, elastin, gelatin, poly-L-lysine, matrigel, proteoglycan, and glycosaminoglycan, and preferably fibronectin.

[0046] The cells cultured on the substrate coated with the above cell adhesion molecules are not limited thereto, but may preferably be stromal cells, which are cells constituting fibrous connective tissue. In this case, the stromal cells may be at least one selected from the group consisting of fibroblasts, chondroblasts, osteoblasts, neuroglial cells, adipocytes, macrophages, and plasma cells.

[0047] The method for producing the multilayered extracellular matrix structure of the present invention is characterized in that it forms a multilayered extracellular matrix by repeatedly performing the steps (d) of culturing cells in (c); and (e) of removing components other than the extracellular matrix in (d). When steps (d) and (e) are performed n times, the multilayered extracellular matrix structure is understood to form n layers. Preferably, the multilayered extracellular matrix structure of the present invention may be one in which steps (d) and (e) are repeated 3 or more times to form 3 or more multilayers. More preferably, steps (d) and (e) may be repeated 4 or more times, and even more preferably, steps (d) and (e) may be repeated 5 or more times.

[0048] In addition, the method for manufacturing the multilayer extracellular matrix structure of the present invention is characterized by including a glycation process. At this time, the glycation may be performed with ribose or glucose, preferably with ribose, and may be performed for 1 day (24 hours) or more, 3 days (72 hours) or more, 1 week or more, 2 weeks or more, or 3 weeks or more, but preferably 3 days (72 hours) or more, more preferably 1 week or more, and most preferably 3 weeks or more. However, the present invention is not limited thereto.

[0049] The multilayered extracellular matrix structure manufactured according to the method for manufacturing the multilayered extracellular matrix structure of the present invention is characterized in that it does not contain nucleic acids and / or lipids by removing components other than the extracellular matrix. In this case, the components other than the extracellular matrix refer to all components excluding the components necessary for the synthesis and maintenance of the extracellular matrix among the nucleic acids, proteins, lipids, carbohydrates, and solution components that constitute the cell.

[0050] In another aspect of the present invention, the present invention provides a multilayered extracellular matrix structure comprising a multilayered extracellular matrix formed on a substrate.

[0051] The multilayer extracellular matrix structure of the present invention may be manufactured according to the “method for manufacturing a multilayer extracellular matrix structure” of the present invention described above, and may be understood to have the same meaning as the in vitro aging model of the multilayer structure in the present invention.

[0052] The substrate is preferably made of glass, but is not limited thereto. If the substrate has a hydrophobic surface, the substrate may be treated with oxygen plasma to convert the surface into hydrophilic.

[0053] The above multilayer extracellular matrix structure may additionally include an acrylate polymer resin to form a multilayer extracellular matrix on a substrate. At this time, the acrylate polymer resin is methyl acrylate, ethyl acrylate, butyl acrylate, 2-carboxyethyl acrylate, methyl methacrylate, ethyl methacrylate, butyl methacrylate, hydroxyalkyl acrylate, hydroxyethyl methacrylate, hydroxyalkyl methacrylate, acrylamide, aminoalkyl acrylate, aminoalkyl methacrylate, tetra(ethylene glycol)dimethacrylate, hydroxypropyl methacrylate, 2-hydroxyethyl acrylate, polyurethane acrylate, polymethyl methacrylate, polyglycidyl methacrylate, 1-vinyl-2-pyrrolidone, di(ethylene glycol)ethyl ether methacrylate, ethylene glycol methyl ether methacrylate,It may be at least one selected from the group consisting of 3-sulfopropyldimethyl-3-methacrylamidopropyl-ammonium, acrylic acid, and methacrylic acid, but is not limited thereto.

[0054] The above multilayered extracellular matrix structure may additionally include cell adhesion molecules to form multilayered extracellular matrices on a substrate. At this time, the cell adhesion molecules may be at least one selected from the group consisting of collagen, fibronectin, laminin, elastin, gelatin, poly-L-lysine, matrigel, proteoglycan, and glycosaminoglycan, and preferably, fibronectin.

[0055] The multilayered extracellular matrix included in the above multilayered extracellular matrix structure is not limited thereto, but may be generated from stromal cells, which are cells that constitute fibrous connective tissue. In this case, the stromal cells may be at least one selected from the group consisting of fibroblasts, chondroblasts, osteoblasts, neuroglial cells, adipocytes, macrophages, and plasma cells.

[0056] The multilayered extracellular matrix structure of the present invention may preferably comprise three or more layers, more preferably four or more layers, and even more preferably five or more layers, and may additionally be glycated.

[0057] The multilayer extracellular matrix structure of the present invention is characterized in that it does not contain nucleic acids and / or lipids by removing components other than the extracellular matrix. In this case, the components other than the extracellular matrix refer to all components excluding the components necessary for the synthesis and maintenance of the extracellular matrix among the nucleic acids, proteins, lipids, carbohydrates, and solution components constituting the cell.

[0058] The multilayer extracellular matrix structure of the present invention may be further glycated, and in this case, the glycation may be performed with ribose or glucose for 1 day (24 hours) or more, 3 days (72 hours) or more, 1 week or more, 2 weeks or more, or 3 weeks or more.

[0059] The multilayered extracellular matrix structure of the present invention can be used for the study of tissue aging. In this case, the structure can be used as an in vitro model for the study of aging of various tissues depending on the type of cell applied. For example, when skin cells are cultured on the multilayered extracellular matrix structure of the present invention, it will serve as an in vitro model for the study of skin tissue aging. When fat cells are cultured on the multilayered extracellular matrix structure of the present invention, it will serve as an in vitro model for the study of fat tissue aging. When muscle cells are cultured on the multilayered extracellular matrix structure, it will serve as an in vitro model for the study of muscle tissue aging. When liver cells are cultured on the multilayered extracellular matrix structure, it will serve as an in vitro model for the study of liver tissue aging. In a preferred embodiment, the multilayered extracellular matrix structure of the present invention is used as an in vitro model for the study of skin aging, but is not limited thereto.

[0060] In another aspect of the present invention, the present invention provides a method for screening a candidate substance for inhibiting tissue aging, comprising the steps of: (a) preparing a multilayered extracellular matrix structure including multilayers of extracellular matrix formed on a substrate; (b) treating the structure with a candidate substance for inhibiting tissue aging; and (c) checking a change in the structure.

[0061] Screening here means selecting a substance with a specific desired property from a candidate group consisting of various substances through a specific manipulation or evaluation method.

[0062] The multilayer extracellular matrix structure used in the screening method of the present invention may be manufactured according to the “method for manufacturing a multilayer extracellular matrix structure” of the present invention described above, and may be understood to have the same meaning as the multilayer structure in vitro aging model in the present invention.

[0063] The limitations of each part of the above “multilayered extracellular matrix structure” and “method for producing a multilayered extracellular matrix structure” overlap with those described above in the specification of the present invention, and are omitted below to avoid excessive complexity of the specification.

[0064] In the above screening method, if, after treating the candidate substance for inhibiting tissue aging, the stiffness and fiber thickness within the sample are significantly reduced, or the adhesion force and pore size are significantly increased, compared to before the treatment, the candidate substance for inhibiting tissue aging can be judged to be effective in inhibiting tissue aging.

[0065] As an opposite example, if, after treating a candidate substance for promoting tissue aging to the multilayer extracellular matrix structure of the present invention, the stiffness and fiber thickness within the sample are significantly increased, or the adhesion force and pore size are significantly decreased, compared to before the treatment, the candidate substance for promoting tissue aging can be judged to be effective in promoting tissue aging.

[0066] The multilayer extracellular matrix structure of the present invention can be used for tissue aging research through a method of testing by appropriately controlling the above-mentioned candidate substances for inhibiting tissue aging and candidate substances for promoting tissue aging.

[0067] Furthermore, by identifying changes in the multilayered extracellular matrix structure using this method, it is possible to develop pharmaceutical, food, or cosmetic compositions for inhibiting or improving tissue aging. Although not limited thereto, the active ingredient of the pharmaceutical, food, or cosmetic composition may be a candidate substance for inhibiting tissue aging derived through the screening method of the present invention.

[0068] Here, the pharmaceutical composition may be, for example, for the inhibition or improvement of skin aging, and further, for the prevention or treatment of various skin diseases caused by skin aging. Here, the pharmaceutical composition may contain a candidate substance for the inhibition of skin aging as an active ingredient, and may additionally contain a protein involved therein and a pharmaceutically acceptable carrier, excipient, or diluent. The "pharmaceutically acceptable" carrier or excipient means one approved by a government regulatory agency or listed in a government or other generally recognized pharmacopoeia for use in vertebrates, and more particularly, in humans. Considering that the pharmaceutical composition of the present invention is applied to skin tissue, the pharmaceutical composition may be in the form of a suspension, solution, or emulsion in an oily or aqueous carrier for parenteral administration, and may be prepared in the form of a solid or semi-solid. In addition, the pharmaceutical composition of the present invention may contain a formulating agent such as a suspending agent, a stabilizer, a solubilizer, and / or a dispersing agent, and may be sterilized. The pharmaceutical composition may be stable under the conditions of manufacture and storage and may be preserved against the contaminating action of microorganisms such as bacteria or fungi. Alternatively, the pharmaceutical composition of the present invention may be in the form of a sterile powder for reconstitution with a suitable carrier prior to use. The pharmaceutical composition may be presented in unit-dose form, in a microneedle patch, in an ampule, or in other unit-dose containers, or in a multi-dose container. Alternatively, the pharmaceutical composition may be stored in a freeze-dried (lyophilized) state requiring only the addition of a sterile liquid carrier, e.g., water for injection, immediately prior to use. Ready-to-inject solutions and suspensions may be prepared as sterile powders, granules, or tablets. In some non-limiting embodiments, the pharmaceutical composition of the present invention may be formulated or incorporated in the form of microspheres in a liquid.In certain non-limiting embodiments, the pharmaceutical compositions of the present invention may comprise pharmaceutically acceptable compounds and / or mixtures thereof at a concentration of between 0.001 and 100,000 U / kg. In certain non-limiting embodiments, the pharmaceutical compositions of the present invention may further comprise suitable excipients such as preservatives, suspending agents, additional stabilizers, dyes, buffers, antibacterials, antifungals, and isotonic agents, for example, sugars or sodium chloride. As used herein, the term "stabilizer" refers to a compound optionally used in the pharmaceutical compositions of the present invention to increase shelf life. In non-limiting embodiments, the stabilizer may be a sugar, an amino acid, or a polymer.

[0069] In addition, the food composition in the present invention may be, for example, intended to inhibit or improve skin aging, and specifically, intended to provide skin antioxidant, whitening, anti-inflammation, and wrinkle improvement. Antioxidation here refers to the inhibition of oxidation, which is the concept of inhibiting cellular aging. Oxygen that enters the body through respiration generates energy necessary for the body while simultaneously generating harmful free radicals. Free radicals attack normal cells in the body and act as a cause of aging and various diseases. Therefore, removing free radicals is a way to prevent cellular oxidation (aging), and inhibiting such cellular oxidation is called antioxidant. Whitening here refers to the function of preventing the increase in melanocytes due to continuous exposure of the skin to ultraviolet rays and the resulting excessive deposition of melanin pigment on the skin, or lightening existing melanin pigment. Accordingly, it can inhibit the formation of blemishes, freckles, age spots, and melanoma caused by excessive melanin pigmentation. Anti-inflammation here refers to the efficacy of soothing and resisting inflammation. Anti-inflammation in the skin can be seen as protecting and stabilizing the skin, and having disinfecting and sterilizing effects. The term "wrinkle" here encompasses externally recognizable wrinkles and internal wrinkles formed at the dermal-epidermal junction. Furthermore, "anti-wrinkle" or "wrinkle inhibition" refers to delaying, inhibiting, or improving the formation of wrinkles. The food composition of the present invention, which includes a candidate substance for inhibiting skin aging derived through the screening method of the present invention, can be manufactured into various food products, such as beverages, gum, tea, vitamin complexes, powders, granules, tablets, capsules, confectionery, rice cakes, bread, etc. The food composition of the present invention is composed of black rice bran and doraji, which are natural foods with virtually no toxicity or side effects, and their bioconverted fermented products, and therefore can be safely used for preventive purposes, even over long periods of time. When the composition of the present invention is included in a food composition, its amount is 0.001% of the total weight.It can be added at a ratio of 1 to 100%. Here, when the food composition is manufactured in the form of a beverage, there is no special limitation other than containing the food composition at the indicated ratio, and various flavoring agents or natural carbohydrates, etc. can be contained as additional ingredients like a typical beverage. That is, as a natural carbohydrate, it can include a monosaccharide such as glucose, a disaccharide such as fructose, a sucrose, and a polysaccharide, a dextrin, a cyclodextrin, and a typical sugar, and a sugar alcohol such as xylitol, sorbitol, and erythritol. As the flavoring agent, natural flavoring agent (thaumatin, stevia extract (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agent (saccharin, aspartame, etc.) can be mentioned. In addition, the food composition of the present invention may contain various nutrients, vitamins, minerals (electrolytes), flavoring agent such as synthetic flavoring agent and natural flavoring agent, coloring agent, pectic acid and its salt, alginic acid and its salt, organic acid, protective colloid thickener, pH adjuster, stabilizer, preservative, glycerin, alcohol, carbonating agent used in carbonated beverage, etc. These components can be used independently or in combination. The ratio of these additives is not so important, but is generally selected in the range of 0.1 to 100 parts by weight per 100 parts by weight of the composition of the present invention.

[0070] In addition, in the present invention, the cosmetic composition may be, for example, for inhibiting or improving skin aging, and specifically, may be for skin antioxidant, whitening, anti-inflammation, and wrinkle improvement. The cosmetic composition of the present invention, which includes a candidate substance for inhibiting skin aging derived through the screening method of the present invention, can be manufactured in the form of a toner, a nutritional lotion, a nutritional essence, a massage cream, a cosmetic bath additive, a body lotion, a body milk, a bath oil, a baby oil, a baby powder, a shower gel, a shower cream, a sunscreen lotion, a sunscreen cream, a suntan cream, a skin lotion, a skin cream, a UV-blocking cosmetic, a cleansing milk, a depilatory agent {cosmetic}, a face and body lotion, a face and body cream, a skin whitening cream, a hand lotion, a hair lotion, a cosmetic cream, jasmine oil, a bath soap, a liquid soap, a cosmetic soap, a shampoo, a hand cleanser (hand cleaner), a medicated soap {non-medical}, a cream soap, a facial wash, a hair rinse, a cosmetic soap, a tooth whitening gel, a toothpaste, etc. To this end, the composition of the present invention may further include an appropriate carrier, excipient, or diluent commonly used in the manufacture of cosmetic compositions. Carriers, excipients, or diluents that may be further added to the cosmetic composition of the present invention include, but are not limited to, purified water, oil, wax, fatty acid, fatty acid alcohol, fatty acid ester, surfactant, humectant, thickener, antioxidant, viscosity stabilizer, chelating agent, buffer, lower alcohol, etc. In addition, whitening agents, moisturizers, vitamins, sunscreens, perfumes, dyes, antibiotics, antibacterial agents, and antifungal agents may be included as needed. As the oil, hydrogenated vegetable oil, castor oil, cottonseed oil, olive oil, palm kernel oil, jojoba oil, and avocado oil may be used, and as the wax, beeswax, spermaceti, carnauba, candelilla, montan, ceresin, liquid paraffin, and lanolin may be used.As fatty acids, stearic acid, linoleic acid, linolenic acid, and oleic acid can be used; as fatty acid alcohols, cetyl alcohol, octyldodecanol, oleyl alcohol, panthenol, lanolin alcohol, stearyl alcohol, and hexadecanol can be used; and as fatty acid esters, isopropyl myristate, isopropyl palmitate, and butyl stearate can be used. As surfactants, cationic surfactants, anionic surfactants, and nonionic surfactants known in the art can be used, and surfactants derived from natural products are preferable if possible. In addition, absorbents, thickeners, and antioxidants widely known in the cosmetics field can be included, and the types and amounts of these are as known in the art.

[0071] Hereinafter, the present invention will be described in detail based on examples.

[0072] The in vitro aging model of the present invention can mimic the three-dimensional structure of various tissues depending on the type of cell applied because it embodies the multilayer ECM structure as it is, and in particular, because it is similar to the ECM structure of skin tissue, it is expected to be greatly utilized in skin aging research.

[0073] Figures 1a to 1e are schematic diagrams of the manufacturing steps of an in vitro aging model (multilayer ECM structure) having a multilayer structure manufactured in the present invention.

[0074] FIG. 2a and FIG. 2b are diagrams showing changes when the cell culture and cell component (CC) removal processes are performed once, twice, three times, four times, or five times in the multilayer ECM structure of the present invention.

[0075] Figures 3a and 3b are diagrams showing changes according to the process of removing cellular components (CC) during the manufacture of a multilayer ECM structure of the present invention.

[0076] FIG. 4 is a diagram showing the detailed composition ratio of each matrix containing ECM proteins and ECM-related proteins within the multilayer ECM structure of the present invention.

[0077] Figures 5a to 5f are diagrams showing a relative quantitative comparison of representative proteins of each group of matrisomes constituting the multilayer ECM structure of the present invention.

[0078] Figures 6a to 6d are diagrams showing changes according to glycation performed during the manufacture of the multilayer ECM structure of the present invention.

[0079] Figures 7 and 8 are diagrams showing the results of protein analysis after the ECM structure of the present invention was saccharified with ribose. Specifically, Figure 7 shows the results of selecting the top 14 proteins according to the degree of saccharification among the matrisomes present in the multilayer ECM structure, and Figure 8 shows the results of confirming the amino acid residues present in the advanced glycation end products for each protein constituting the multilayer ECM structure and the type of advanced glycation end product for each amino acid residue through protein mass spectrometry.

[0080] Figures 9 to 11 are diagrams showing the results of proteomic analysis of the ribose-glycated ECM structure of the present invention. Specifically, Figure 9 shows amino acid residues in which advanced glycation end products (AGEs) are identified in the full-length protein of fibronectin, Figure 10 shows amino acid residues in which advanced glycation end products (AGEs) are identified in the full-length protein of collagen type I, and Figures 11a and 11b show the results of GO (Gene ontology) analysis using the top 14 glycated proteins described in Figure 7.

[0081] Figures 12 to 15 are diagrams showing the results of proteomic analysis of the ECM structure glycated with glucose of the present invention. Specifically, Figure 12 shows the results of selecting the top 17 proteins according to the degree of glycation among the matrisomes present in the multilayer ECM structure, and Figure 13 shows the results of showing advanced glycation end products identified through proteomic mass spectrometry. Figure 14 shows amino acid residues in which advanced glycation end products are identified in the full-length protein of fibronectin, and Figure 15 shows amino acid residues in which advanced glycation end products are identified in the full-length protein of collagen type I.

[0082] Figures 16 and 17 show the results of analyzing the effect of acrylate polymer resin coating in the production of a multilayer ECM structure of the present invention. Specifically, Figure 16 shows the results of producing a multilayer structure when no polymer is coated, and Figure 17 shows the results of producing a multilayer structure when coated with PDMS as a non-acrylate polymer resin.

[0083] Glass cover glasses were treated with oxygen plasma, coated with an acrylate polymer resin, and then further coated with fibronectin, on which NIH / 3T3 cells were seeded. The cells were cultured until they reached 100% confluency on the cover glass surface, and then the cellular component (CC) was removed to extract only the highly pure extracellular matrix (ECM). The cells were washed three or more times with DPBS (Dulbecco's phosphate buffer saline), and cell culture was re-performed on a single layer of ECM. When the cells reached 100% confluency, the ECM was re-extracted. By repeating the cell culture and ECM extraction steps, a multilayered in vitro aging model was produced. Finally, the produced multilayered ECM was incubated in ribose dissolved in DPBS for 37 min. oBy maintaining the C condition and reacting for 3 weeks, an in vitro aging model with a glycated multilayer structure was manufactured.

[0084] Hereinafter, the present invention will be described in detail with reference to the following examples. However, the following examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following examples.

[0085] Example

[0086] Example 1. Preparation of an in vitro aging model with a multilayer structure

[0087] The hydrophobic surface of a glass cover glass was temporarily converted to hydrophilic by treating it with oxygen plasma at 30 W for 1 minute. This was coated with an acrylate polymer resin (PUA), and then an additional 37 o After coating with fibronectin for more than 4 hours in C, placed in a 35pi petri dish, 1x10 4 / cm 2 NIH / 3T3 cells were seeded. The cells were cultured to form 100% confluency on the cover glass surface, and the cellular component (CC) was removed by treating with an extraction buffer containing 0.1% sodium dodecyl sulfate (SDS), 0.1% Triton X-100, and 0.001% poly-L-lysine (PLL) to extract only the highly pure extracellular matrix (ECM). The cells were washed three or more times with Dulbecco's phosphate buffer saline (DPBS), and the cells were cultured again on the ECM monolayer. When the cells formed 100% confluency, the ECM was re-extracted. By repeating the cell culture and ECM extraction steps, a multilayered in vitro aging model was manufactured. Finally, the produced multilayer ECM was dissolved in 500 mM ribose or glucose in DPBS at 37 oA glycated model was produced by reacting for 3 weeks while maintaining the C condition. The manufacturing method of the in vitro aging model of the multilayer structure of the present invention is schematically shown in Figures 1a to 1e.

[0088] Example 2. Validation of the utility of a multilayer in vitro aging model.

[0089] [Experimental Method]

[0090] 1. Immunostaining

[0091] After washing the sample with DPBS, it was fixed with 4% paraformaldehyde solution at room temperature for 20 minutes, and then permeabilized with 0.15% (v / v) Triton X-100 solution at room temperature for 15 minutes. The sample was washed and blocked with 1% (w / v) bovine serum albumin (BSA) solution at room temperature for 1 hour to prevent nonspecific binding. The primary antibody was diluted in 1% (w / v) BSA solution and incubated for 4 o The cells were treated at C for 16-24 hours, and the secondary antibody was treated at room temperature for 1 hour 30 minutes to 2 hours. Afterwards, phalloidin was treated at a concentration of 5 μg / ml for 45 minutes at room temperature, and DAPI was treated at a concentration of 4 μg / ml for 15 minutes at room temperature. After washing, the cells were sealed and completely dried, and then stored at -20 o C or -80 o Stored in C.

[0092] 2. Scanning electron microscope imaging

[0093] After washing the sample with DPBS, it was first fixed with a 2% (v / v) glutaraldehyde solution at room temperature for 30 minutes, and second fixed with a 1% (v / v) osmium tetroxide solution for 30 minutes at room temperature. After that, the sample was dehydrated by gradually permeating it with 25%, 50%, 75%, 95%, 100%, and 100% (v / v) ethanol solutions at room temperature for 10 minutes each, and then treated with tertiary butyl alcohol solution three times for 30 minutes each at room temperature, followed by freeze-drying to completely dry the sample. This was firmly attached to the scanning electron microscope stub using carbon double-sided tape and silver paste, and platinum was coated for 1 minute and 30 seconds at 20 mA, and scanning electron microscopy images were taken.

[0094] 3. Proteomic mass analysis of multilayer cell-derived extracellular matrix

[0095] Cell-derived extracellular matrix was harvested from cover glass using a cell scraper and dissolved in a buffer consisting of 5% (w / v) sodium dodecyl sulfate (SDS), 50 mM triethylammonium bicarbonate (TEAB), and pH 8.5. The supernatant was centrifuged at 13,000 rpm for 8 minutes, and protein quantification was performed using the bicinchoninic acid (BCA) method. The sample was reduced by treating with 5 mM TCEP (Tris(2-carboxyethyl)phosphine) for 10 minutes, alkylated using iodoacetamide (IAA) diluted in isopropyl alcohol, and diluted with a phosphoric acid solution. The protein was purified by mixing 300 μg of protein with a binding / wash buffer consisting of a TEAB solution diluted to 100 mM in 90% methanol and filtering through an S-Trap column three times, and trypsin diluted to 50 mM TEAB solution was added to this. o 1-2 hours at C or 37 oThe protein was degraded by treatment at C for 16 hours. After that, the sample was diluted with 50 mM TEAB solution, centrifuged at 4,000 rcf for the first time, added 0.2% formic acid solution, centrifuged a second time, added 50% diluted acetonitrile solution, centrifuged a third time, eluted peptides were dried, and resuspended in 0.1% formic acid solution for mass spectrometry. The sample was analyzed for peptides by reversed-phase-High Performance liquid chromatography (RP-HPLC) using a 75 μm x 50 cm analytical column, and MS / MS analysis data were integrated and analyzed using IP2 software based on the Uniprot database. Specifically, data was recognized as peak units, and information such as mass / charge (m / z) of the peak was extracted, and then information such as amino acid sequence was confirmed in the database, and protein identification was performed by comparing it with the spectrum of the obtained peptide. The precursor mass error was 4.5 ppm, the fragment ion mass error was 20 ppm, and the false discovery rate (FDR) was set to 0.01 for peptide spectrum matching and protein identification using the target decoy strategy.

[0096] 4. Measurement of elastic modulus of multilayer cell-derived extracellular matrix

[0097] Preprocessing for elastic modulus measurement was performed in the same manner as the dehydration process for the scanning electron microscope imaging described above. To measure the force-distance curve of the sample using an atomic force microscope, a cantilever with an appropriate spring constant was fixed to a metal chip carrier and mounted on the atomic force microscope. The sample, completely dried through freeze-drying, was then placed on the sample stage of the atomic force microscope, and the superluminescent diode was aligned with the tip of the cantilever and the center of the optical position detector, and contact mode was activated. The probe was moved close to the sample, and the gap between the sample and the probe was precisely adjusted at an appropriate location. Setting values ​​for the probe's z-axis movement range, speed, and force intensity limit were input, and the force-distance curve was repeatedly measured at multiple locations within the sample. The measured force-distance graph data were entered into the Hertz model conversion formula to calculate the elastic modulus at each location within the sample. The Poisson's ratio was calculated to be 0.5.

[0098] [Experimental Results]

[0099] 1. Confirmation of changes in ECM lamination

[0100] To determine changes in the structure due to the deposition of ECM layers, the topology of samples subjected to cell culture and cell component (CC) removal processes once, twice, three times, four times, or five times was measured. The results are shown in Figs. 2a and 2b.

[0101] As a result of the test, the laminated ECM thickness (Z) was 6-10 μm when the cell culture and CC removal process was performed once, 10-16 μm when performed twice, 15-17 μm when performed three times, 22-25 μm when performed four times, and 33-40 μm when performed five times, showing that the ECM thickness increased as the cell culture and CC removal processes were repeated. The size of the fibronectin bundles (FN bundels) in the sample was 5.84 μm on average when the cell culture and CC removal process was performed once, 7.12 μm on average when performed twice, 8.33 μm on average when performed three times, 10.04 μm on average when performed four times, and 13.56 μm on average when performed five times, showing that it also increased as the cell culture and CC removal processes were repeated in the same pattern as the ECM thickness.

[0102] 2. Confirm removal of CC in ECM

[0103] To confirm that cellular components (CC) other than ECM were properly removed from samples subjected to cell culture and CC removal processes, samples before and after CC removal were immunostained and compared. The results are shown in Figures 3a and 3b.

[0104] As a result of the test, in the sample before the CC removal process, ECM components such as Collagen I, Collagen IV, Fibronectin, Laminin, and Elastin were stained together with the cell nuclei, but in the sample after the CC removal process, all of the ECM components were still present and only the cell nuclei were removed, confirming that only the cell components (CC) other than the ECM were successfully removed through the CC removal process. The results of checking the DNA concentration in the two samples also showed that the cell nuclei and nucleic acids were well removed through the CC removal process.

[0105] 3. Proteomic analysis of multilayer ECM

[0106] The results of proteomic analysis on a multilayer ECM sample in which cell culture and CC removal processes were repeated five times are shown in Figures 4 and 5.

[0107] Figure 4 shows that the proteomic analysis of the present invention divides the matrisome, which includes ECM proteins and ECM-associated factors, into a core matrisome and matrisome-associated proteins, thereby showing how diverse the multilayered cell-derived ECM of the present invention contains matrisome components.

[0108] As a result of the test, it was analyzed that the multilayered ECM sample of the present invention contained 123 proteins among the entire matrisome. Among them, the core matrisome contained 62 proteins and the matrisome-related proteins contained 61 proteins. Specifically, the core matrisome contained 17 collagens, 38 ECM glycoproteins, and 7 proteoglycans, and the matrisome-related proteins contained 11 secreted factors, 15 ECM-affiliated proteins, and 35 ECM regulators.

[0109] Figures 5a to 5f show a list of representative proteins for each group, enabling a relative quantitative comparison of the proteins. The emPAI index formula used for this purpose was referenced from prior literature in the field (Ishihama, Yasushi, et al. "Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein" Molecular & Cellular Proteomics 4.9 (2005): 1265-1272.), and the database for matrisome analysis was also a known database (Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, and Hynes RO. The matrisome: in-silico definition and in-vivo characterization by proteomics of normal and tumor extracellular matrices. Molecular and Cellular Proteomics, 2012, 11(4):M111.014647. https: / doi.org / 10.1074 / mcp.M111.014647). As a result of the analysis, it was confirmed that among the core matrisomes, collagens were mainly rich in the α1 chain of collagen XII, α1 and α2 chains of collagen I, and α1 and α2 chains of collagen VI, ECM glycoproteins were mainly rich in fibronectin and EMILIN-1, and proteoglycans were mainly rich in the basement membrane-specific HSPG core protein, biglycan, prolargin, and versican.Among the matrisome-related proteins, it was confirmed that the secretory substances mainly include Angiopoietin-related protein 2, S100A4, and EGF-like protein 7, ECM-related proteins mainly include Annexin A2 and A1, and ECM regulatory substances mainly include protein lysine 6 oxidase, serpin H1, and transglutaminase 2. This means that the ECM structure of the present invention is composed of a wide variety of ECM components, and can mimic natural ECM.

[0110] 4. Confirmation of the structure and properties of the glycated multilayer ECM

[0111] The changes before and after performing the glycation process with ribose on the multilayered ECM sample of the present invention were analyzed, and the results are shown in Figures 6a to 6d.

[0112] Immunostaining tests showed that glycation resulted in the formation of a large amount of advanced glycation end-products (AGEs) and their accumulation within the ECM, and that the fluorescence intensity of ECM components (collagen I, collagen IV, fibronectin, laminin, and elastin) significantly increased. Furthermore, physical analysis revealed that glycation significantly increased the stiffness and fiber thickness of the samples, while significantly decreased the adhesion force and pore size. This suggests that glycation physically strengthened the ECM structure.

[0113] 5. Proteomic analysis of glycated multilayer ECM

[0114] The results of proteomic analysis of multilayer ECM samples that underwent cell culture and CC removal processes five times and were saccharified with ribose or glucose are shown in Figures 7 to 15. The 'degree of saccharification' was compared / analyzed based on the total amount of all advanced glycation end products confirmed through proteomic analysis in each ECM protein, and the sample that was not saccharified as a control was indicated as 'native'.

[0115] Figures 7 to 11 show the results of ribose-based glycation, and Figure 7 shows the results of proteomic analysis after glycation of multilayered cell-derived ECM, showing the top 14 proteins according to the degree of glycation among the matrisomes present in the sample. As a result of the analysis, even with the same glycation induction period (7 days), a relatively large amount of advanced glycation end products (AGEs) accumulated in Fibronectin, Collagen I, and Collagen XVI, indicating that even if the glycation process is induced for the same period, the degree of AGEs formed may differ. The amount of AGEs comprehensively increased depending on the glycation treatment period.

[0116] Figure 8 shows advanced glycation end products (AGEs) identified through proteomic mass spectrometry. The amino acid residues at which AGEs are present, along with the types of AGEs at each amino acid residue, are indicated for each protein constituting the cell-derived ECM used as a sample. It is known that the glycation process induces the formation of AGEs only at lysine and arginine residues in proteins, and thus, no AGEs were detected at any other amino acid residues. Furthermore, the types of AGEs formed varied depending on the amino acid residue. For example, GH, G-DH, MG-H, and MG-DH were formed at arginine residues, while Amadori products, CML, and CEL were formed at lysine residues. Therefore, it was found that the pattern of AGE formation can vary for each ECM protein even with the same glycation induction period.

[0117] Figure 9 shows the amino acid residues in which advanced glycation end products (AGEs) are identified within the full-length fibronectin protein. Fibronectin is composed of three types of modules (type-Ⅰ, type-, and type-Ⅲ), an extra domain, and a variable region, and each module assembles to form a functional domain. For example, modules 1 to 5 assemble to form a fibrin- and heparin-binding domain, which means that fibrin or heparin can bind to modules 1 to 5 of fibronectin when interacting with fibronectin. Referring to Figure 9, it can be confirmed what functional domains are formed when each module assembles within fibronectin and collagen type I. Figure 9 also shows the positions of residues among all amino acid residues constituting fibronectin where formation of advanced glycation end products (AGEs) through ribose glycosylation has been confirmed. Those starting with R- indicate arginine, and those starting with K indicate lysine. For example, K249 indicates that lysine residues are present at position 249 among the amino acid residues constituting fibronectin, confirming the formation of AGEs at this position.

[0118] Figure 10 shows amino acid residues identified as advanced glycation end products within the full-length protein of collagen type I. The symbols and method of representation in the drawing are the same as those in Figure 9.

[0119] In summary, Figures 9 and 10 show that the positions of amino acid residues of advanced glycation end products formed by the glycosylation process may differ depending on the ECM protein, and that advanced glycation end products are formed at much more positions in fibronectin compared to collagen I.

[0120] Figures 11a and 11b show the results of GO (Gene Ontology) analysis using the top 14 glycated proteins described in Figure 7. Referring to Figure 11, it can be seen that the ECM proteins modified by the glycation process are proteins that play a crucial role in cell adhesion. This means that these proteins are molecularly involved in ECM structure and play a crucial function in binding to cell adhesion molecules, including integrins.

[0121] Figures 12 to 15 show the results of glucose saccharification, and Figure 12 shows the results of proteomic analysis after saccharification of a multilayered cell-derived ECM, showing 17 top proteins according to the degree of glycation among the matrisomes present in the sample. This shows that even if the period of glucose treatment is the same depending on the ECM protein, that is, the period of saccharification induction is the same, the degree of formation of advanced glycation end products may differ. Relatively large amounts of AGE accumulation were confirmed in fibronectin, Annexin A1, Annexin A2, Annexin A4, and lactadherin. The 'total' in the last row compares the total amount of advanced glycation end products (AGEs) present in all ECM proteins where glycation was induced at each time point, showing that the amount of AGEs comprehensively increases depending on the duration of glucose treatment. Compared to Figure 7, which shows the results using ribose, it can be confirmed that the types of ECM proteins in which significant changes were induced due to glycation are very different. This means that the composition of the primary target protein can vary depending on the type of sugar molecule that induces glycation, and the rate of glycation reaction and the degree of change induced can also vary.

[0122] Figure 13 shows the results of AGEs identified through proteomic mass spectrometry. The amino acid residues at which AGEs exist for each protein constituting the cell-derived ECM used as a sample and the type of AGEs for each amino acid residue are indicated. As with ribose glycation, it can be confirmed that the formation of AGEs was not detected for amino acid residues other than lysine and arginine residues in the protein during the glucose-based glycation process. In addition, there are various types of AGEs, and the type of AGEs formed differs depending on the amino acid residue depending on the reaction, showing that the glucose-based glycation process produces different types of AGEs than the ribose-based glycation process shown in Figure 8. For reference, in glucose glycation, AGEs such as GH, G-DH, MG-H, MG-DH, IB, D-GH, DG-DH, and Argp are known to be formed mainly at arginine residues, while AGEs such as FL, CEL, Pyr, CML, AFGP, and GP are formed mainly at lysine residues. In addition, just like ribose, it was confirmed that the pattern of AGE formation can be different for each ECM protein even if the glycation process was induced by exposure to glucose for the same period of time. However, it was shown that AGEs were accumulated mainly at lysine rather than arginine in most proteins, and furthermore, it was found that they showed a more monotonous pattern of change than glycation due to ribose.

[0123] Figures 14 and 15 show all amino acid residues identified as advanced glycation end products in the full-length proteins of fibronectin (Fn) and collagen type Ⅰ (Col Ⅰ) due to the glucose glycation process. First, Figure 14 is a diagram showing full-length fibronectin. Fibronectin is composed of three types of modules (type-Ⅰ, type-, type-Ⅲ), an extra domain, and a variable region, and each module comes together to form a functional domain. For example, modules 1 to 5 come together to form a fibrin- and heparin-binding domain, which means that fibrin or heparin can bind to modules 1 to 5 of fibronectin when interacting with fibronectin. Referring to Figure 14, it can be confirmed what functional domain each module comes together to form within fibronectin and collagen type I. Figure 14 also shows the positions of residues among all amino acid residues constituting fibronectin at which the formation of advanced glycation end products (AGEs) by glucose glycation was confirmed. Starting with R- indicates the position of arginine, and starting with K indicates the position of lysine. For example, K204 indicates that there is a lysine residue at position 204 among the amino acid residues constituting fibronectin, and it shows that the formation of AGEs was confirmed at this position. Figure 15 is a diagram showing full-length collagen type I. The upper part represents the alpha 1 chain of collagen type I, and the lower part represents the alpha 2 chain of collagen type I. Similarly, the functional domains and the positions of amino acid residues confirmed to form advanced glycation end products in collagen type I are indicated.

[0124] In summary, we can confirm that the positions of amino acid residues of advanced glycation end products (AGEs) formed by glycation differ depending on the ECM protein. Comparatively, AGEs were formed at significantly more positions in fibronectin than in collagen type I, and glycation by ribose and glycation by glucose formed AGEs at different positions in the same ECM protein. In other words, this indicates that although glycation targets the same protein, the functional domain affected within the protein can differ depending on the glycation inducer. This means that even in the same glycation process, the direction and method of protein modification can differ depending on the sugar molecule.

[0125] 6. Analysis of the Effect of Acrylate Polymer Resin Coating on Multilayer ECM

[0126] In the manufacture of multilayer ECMs, acrylate polymer resin coatings and non-acrylate polymer resin coatings can produce different results. Experimental results for this are shown in Figs. 16 and 17.

[0127] Figure 16 shows the appearance of extracellular matrix structures formed on a glass surface after plasma treatment without any polymer coating. Even a single layer of extracellular matrix structures does not adhere well to the glass surface and is observed to peel off. The dotted line indicates the boundary of the extracellular matrix structures adhered to the glass surface. The extracellular matrix on the left side of this line is detached from the surface and overlaps with the structures on the right side.

[0128] Figure 17 shows the results of laminating extracellular matrix structures on glass coated with PDMS (polydimethylsiloxane), a non-acrylate polymer resin, rather than an acrylate polymer after plasma treatment. Unlike when the glass was not coated with anything, when PDMS was coated, a single layer of extracellular matrix structures adhered well to the glass surface, and the nanofiber network within the extracellular matrix maintained its shape well. However, during the subsequent lamination of multiple layers of extracellular matrix structures, the lowest structures exhibited unstable adhesion, and in particular, when the third layer was laminated, some of them were completely detached from the glass surface due to the contractile force of the recultured cells. The area of ​​detached extracellular matrix structures is indicated by a dotted line. These differences compared to acrylate polymer resin coatings are believed to be due to the fact that, unlike non-acrylate polymers, acrylate polymers possess highly polar ester groups, resulting in higher adhesion strength. Furthermore, acrylate polymers possess a good balance between flexibility and rigidity, making them advantageous for supporting structures or maintaining structural deformation, while simultaneously providing adequate long-term stability. Consequently, the use of acrylate polymers is expected to complement the weak adhesion between the glass surface and the extracellular matrix structures, enabling the stable production of multilayered extracellular matrices.

[0129] While specific aspects of the present invention have been described in detail above, it should be apparent to those skilled in the art that these specific descriptions are merely preferred embodiments and do not limit the scope of the present invention. Therefore, the substantial scope of the present invention is defined by the appended claims and their equivalents.

[0130] The in vitro aging model including the extracellular matrix of the present invention with a multilayered structure can mimic the three-dimensional structure of various tissues depending on the type of cells applied because it embodies the multilayered ECM structure as it is, and in particular, because it is similar to the ECM structure of skin tissue, it is expected to be greatly utilized in skin aging research.

Claims

1. (a) A step of coating a cell adhesion molecule on a hydrophobic substrate; (b) a step of culturing cells in the above (a); (c) a step of removing components other than the extracellular matrix in (b); and, (d) A method for producing a multilayer extracellular matrix structure, comprising a step of glycating the above (c).

2. In paragraph 1, A manufacturing method wherein the above hydrophobic substrate is a substrate made of glass.

3. In paragraph 1, A manufacturing method, wherein the cell adhesion molecule is at least one selected from the group consisting of collagen, fibronectin, laminin, elastin, cadherin, integrin, selectin, proteoglycan, and glycosaminoglycan.

4. In paragraph 1, A manufacturing method wherein the cells of step (b) above are stromal cells.

5. In paragraph 4, A manufacturing method, wherein the above-mentioned stromal cells are at least one selected from the group consisting of fibroblasts, chondroblasts, osteoblasts, neuroglial cells, adipocytes, macrophages, and plasma cells.

6. In paragraph 1, The above manufacturing method is a manufacturing method in which steps (b) and (c) are repeated three or more times.

7. In paragraph 1, A manufacturing method wherein the above saccharification is performed with ribose or glucose.

8. In paragraph 1, A manufacturing method wherein the above saccharification is performed for 3 days or more.

9. In paragraph 1, A manufacturing method, wherein the components other than the extracellular matrix of step (c) above include nucleic acids and lipids.

10. A multilayered extracellular matrix structure comprising multilayered extracellular matrix formed on a substrate.

11. In paragraph 10, A structure in which the above substrate is a substrate made of glass material.

12. In paragraph 10, A structure in which the above multilayer has three or more layers.

13. In paragraph 10, A structure wherein the above extracellular matrix is ​​an extracellular matrix derived from stromal cells.

14. In paragraph 13, A structure wherein the above-mentioned stromal cells are at least one selected from the group consisting of fibroblasts, chondroblasts, osteoblasts, neuroglial cells, adipocytes, macrophages, and plasma cells.

15. In paragraph 10, A structure wherein the above structure does not contain nucleic acid and lipid components.

16. In paragraph 10, The above structure is a structure for tissue aging research. 17.(a) A step of manufacturing a multilayered extracellular matrix structure including a multilayered extracellular matrix formed on a substrate; (b) a step of treating the structure with a candidate substance for inhibiting tissue aging; and, (c) A method for screening a candidate substance for inhibiting tissue aging, comprising a step of confirming a change in the above structure.

18. In paragraph 17, A screening method wherein the above tissue is skin tissue.

Citation Information

Patent Citations

  • Wet 3D cell printing using decellularized extracellular matrix

    KR1020180049712A

  • High temperature pellet agglomeration prevention system

    KR1020240023824A

  • KR20190003061A

  • KR20230046958A